BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (JAN FEB 2019)

Formulation Development: Moxifloxacin Nanoparticles

Upadhyay Shivam U1, Upadhyay Umeshkumar M2 & Patel Jayvadan K3

Introduction:

Abstracts: Moxifloxacin (MOX) is a water soluble fluoroquinolone anti-infective drug, indicated for the treatment of bacterial conjunctivitis. Aim of the present study was to formulate, optimize and characterize polymeric nanoparticles of MOX for ocular administration. MOX and IER compatibility study was done with FT-IR. Nanoparticles of Ion Exchange Resin (IER) were prepared by media milling method and formulation/process parameters were optimized. MOX was entrapped in IER nanoparticles. Sedimentation behaviour was studied for IER nanoparticles. Nanoparticles were characterized for particle size and zeta potential. 95% drug was entrapped at 1:1 stoichiometric ratio of MOX and IER in nanoparticles. Mean particle size of nanoparticles was 301 nm and zeta potential of -37.8 mV exhibiting physically stable formulation. MOX-IER nanoparticles were of neutral pH suitable to deliver on to ocular surface. In vitro release study exhibited sustained release pattern of MOX from nanoparticles following Korsmeyer-Peppas model. Drug was found to be released by Fickian diffusion mechanism. Based on these results it can be hypothesized that MOX-IER nanoparticles is suitable for ocular delivery.

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.